Can I Take Calcium with Belsomra (Suvorexant)?

What Is Suvorexant and How Does It Work?

Suvorexant blocks the orexin-1 and orexin-2 receptors in the hypothalamus. Orexin (also called hypocretin) is the neuropeptide system that keeps the brain awake. Blocking it reduces the drive to stay awake rather than forcing sedation through GABA pathways the way older sleep drugs do.

The FDA approved suvorexant in August 2014 under the brand name Belsomra for adults with insomnia characterized by difficulty falling and staying asleep. The approved dose range is 5 to 20 mg taken no more than once per night, within 30 minutes of going to bed. [1]

CYP3A4 as the Key Metabolic Pathway

Suvorexant is metabolized almost entirely by hepatic CYP3A4. Its half-life is approximately 12 hours. The prescribing information states that strong CYP3A4 inhibitors (such as ketoconazole) substantially increase suvorexant exposure and that the drug is contraindicated with strong CYP3A4 inducers. [1] Calcium has no known effect on CYP3A4 activity, which is the primary reason no pharmacokinetic interaction is expected.

What Suvorexant Does Not Do

Suvorexant does not significantly affect GI motility or gastric pH at therapeutic doses. It does not chelate minerals. It is not renally cleared as an unchanged compound. These facts matter because several proposed supplement interactions with sleep drugs involve one of those three mechanisms. None applies here.

What Is Calcium Doing in Your Body and Why Might It Interact with Drugs?

Calcium is the most abundant mineral in the human body. About 99% of it is stored in bone, with the remaining 1% tightly regulated in serum (normal range 8.5 to 10.5 mg/dL). [2]

How Calcium Supplements Are Absorbed

The two most common supplement forms are calcium carbonate and calcium citrate. Calcium carbonate requires gastric acid and should be taken with meals. Calcium citrate does not require acid and may be taken without food, making it the preferred choice for people on proton pump inhibitors or histamine-2 blockers. Recommended elemental calcium intake for adults aged 19 to 50 years is 1,000 mg per day, rising to 1,200 mg per day for women over 50 and men over 70, per the National Institutes of Health Office of Dietary Supplements. [2]

Why Calcium Can Interact With Other Drugs

Calcium ions bind to certain drug molecules in the GI tract through chelation, reducing absorption. This is why calcium must be separated by at least 2 hours from bisphosphonates like alendronate, and by at least 4 hours from levothyroxine in many patients. A 2017 review in the Annals of Pharmacotherapy confirmed that calcium carbonate coadministration reduces levothyroxine bioavailability by approximately 20 to 40 percent. [3]

Suvorexant is not absorbed via a mechanism susceptible to chelation. It is a small lipophilic molecule, not a bisphosphonate or a thyroid hormone analog. Calcium does not bind it in the gut.

Is There a Recognized Interaction Between Calcium and Belsomra?

No. The FDA prescribing label for suvorexant does not list calcium or any calcium-containing compound as an interacting agent. [1] The label's drug interaction table focuses on CYP3A4 modulators (ketoconazole, diltiazem, rifampin), CNS depressants, and alcohol.

Checking the Established Interaction Databases

The Natural Medicines database (formerly Natural Medicines Comprehensive Database) classifies the calcium-suvorexant combination as having no known interaction. Pharmacist-reviewed interaction checkers at major academic medical centers similarly return no flag for this pair.

Peer-reviewed pharmacology literature does not contain a single published case report or controlled study demonstrating altered suvorexant pharmacokinetics in the presence of calcium supplementation.

What the FDA Label Does Warn About

The label warns about three interaction categories that are worth knowing even if calcium is not one of them:

1. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) can raise suvorexant plasma concentrations to potentially unsafe levels. The label states the combination is not recommended.
2. Moderate CYP3A4 inhibitors (diltiazem, verapamil, fluconazole) increase suvorexant area-under-the-curve by roughly 2-fold. The starting dose should not exceed 5 mg with these agents.
3. CNS depressants, including opioids, benzodiazepines, and alcohol, increase the risk of additive sedation and next-morning impairment. [1]

Calcium fits none of these categories.

Pharmacokinetics in Detail: Why Calcium Cannot Meaningfully Interfere

Suvorexant has an oral bioavailability of approximately 82% under fasting conditions. Food delays the time to maximum concentration by about 1.5 hours but does not reduce the total amount absorbed. Peak plasma concentration (Tmax) is reached in about 2 hours under fasting conditions. [1]

Protein Binding and Distribution

Suvorexant is greater than 99% protein-bound in plasma, primarily to albumin. Calcium does not compete with albumin binding sites used by suvorexant. The two molecules occupy entirely different binding domains.

Renal and Hepatic Handling

Suvorexant undergoes extensive hepatic metabolism to an inactive hydroxyl-suvorexant metabolite, again via CYP3A4. Less than 1% is excreted unchanged in urine. Calcium, by contrast, is filtered and reabsorbed by the kidney through entirely separate transport channels (TRPV5, TRPV6 channels regulated by parathyroid hormone and calcitriol). [3]

There is no shared elimination pathway.

The Indirect Concern: Calcium's Cardiovascular and Neurological Context

While calcium does not interact with suvorexant directly, the broader context of why a person takes both is worth examining.

Calcium and Sleep Quality

Some small studies have suggested that calcium may support sleep by contributing to the synthesis of melatonin, since the enzyme that converts serotonin to melatonin (AANAT) is calcium-dependent. A 2013 study published in Medical Hypotheses proposed that calcium deficiency may disrupt sleep architecture. [4] This is a hypothesis-generating observation, not a confirmed mechanism, and it does not imply calcium supplements will reduce or enhance suvorexant's effect in a clinically meaningful way.

Hypercalcemia and Neurological Symptoms

Calcium toxicity at elevated serum levels (above 12 mg/dL) can cause confusion, cognitive slowing, and fatigue. If someone were taking very high calcium doses while on suvorexant, excess sedation or cognitive fog could theoretically be attributed to hypercalcemia rather than a drug interaction. This is a reason to stay within recommended calcium intake limits, not a reason to avoid the combination.

The tolerable upper intake level for calcium in adults is 2,500 mg per day (ages 19 to 50) or 2,000 mg per day (ages 51 and older), per the NIH Office of Dietary Supplements. [2] Standard supplement doses of 500 to 1,000 mg per day sit well below these thresholds.

Cardiovascular Considerations

There has been ongoing scientific debate about whether high-dose calcium supplementation (typically above 1,000 mg per day from supplements, not diet) raises cardiovascular risk. A 2019 meta-analysis in the BMJ (N=72,348 across 15 randomized trials) found no significant association between calcium supplementation and cardiovascular events when dietary calcium was considered together with supplement intake. [5] Suvorexant itself was not associated with cardiac adverse events in the key Phase 3 trial program submitted to the FDA. These are independent risk profiles that do not compound each other.

Special Populations: Who Should Exercise Extra Care?

Even when a direct drug-supplement interaction does not exist, certain patient groups deserve individualized attention.

Older Adults

Adults over 65 taking suvorexant already face a higher baseline risk of next-morning sedation, falls, and cognitive impairment. The American Geriatrics Society 2023 Beers Criteria caution against orexin receptor antagonists in older adults due to fall risk. Adding high-dose calcium supplements in this population is generally considered low risk for drug interaction, but the combination of sedation from suvorexant and the muscle and bone context of calcium use means a prescriber should review the full medication list. [6]

People on Bisphosphonates or Thyroid Medication

This is the scenario where calcium timing matters most, though the interaction is with those other drugs, not with suvorexant. If you take alendronate (Fosamax), risedronate, or levothyroxine, separate those doses from calcium by at least 2 to 4 hours. Suvorexant is taken at bedtime. Bisphosphonates and levothyroxine are typically taken in the morning, so the schedule works out naturally for most people.

People Taking Diuretics

Thiazide diuretics reduce urinary calcium excretion, which can raise serum calcium. Loop diuretics do the opposite, increasing calcium loss. If you are on a diuretic alongside suvorexant and calcium, your prescriber may want to monitor serum calcium periodically, not because of a suvorexant interaction, but to ensure the diuretic is not pushing calcium out of the target range.

How to Take Both Safely: Practical Timing Guide

Because no pharmacokinetic interaction exists, there is no mandatory separation window between calcium and suvorexant. But practical timing advice still helps optimize both agents.

Morning (with breakfast)

• Calcium citrate 500 mg (or calcium carbonate 500 mg if taken with food)
• Any thyroid or bisphosphonate medication should be taken 30 to 60 minutes before this, or separated by at least 2 to 4 hours

Evening (with dinner if using carbonate, or without food if using citrate)

• Second calcium dose (500 mg) if your total daily target is 1,000 mg

Bedtime (within 30 minutes of intended sleep)

• Suvorexant 10 mg (or your prescribed dose, up to 20 mg)
• Do not take with or immediately after a high-fat meal, as this delays suvorexant absorption without meaningfully increasing total exposure [1]

This schedule avoids any theoretical gastric competition, keeps calcium below single-dose thresholds that can reduce absorption of other drugs, and matches suvorexant's label instructions exactly.

What the Clinical Trials Tell Us About Suvorexant Safety

The key Phase 3 trial for suvorexant was a 3-month randomized, double-blind, placebo-controlled study (N=1,021) that demonstrated suvorexant 15 mg and 20 mg significantly reduced time to sleep onset compared to placebo (P<0.001). A 12-month long-term safety study (N=521) found no new safety signals during extended use, with the most common adverse event being somnolence (7% with suvorexant vs. 3% with placebo). [7] Neither trial screened for or analyzed calcium intake, which itself reflects the lack of concern about this combination.

The NEJM 2014 paper describing the compound's approval pathway noted that next-day driving impairment, not mineral interactions, was the central safety concern during development. [8]

Monitoring: What to Watch When Taking Both

Routine lab monitoring is not required for the suvorexant-calcium combination. Certain symptoms warrant a call to your prescriber.

Symptoms That Could Signal Hypercalcemia (Not a Drug Interaction)

• Persistent nausea, constipation, or abdominal pain
• Muscle weakness or unusual fatigue
• Confusion or difficulty concentrating
• Increased thirst and frequent urination

A serum calcium level (included in a basic metabolic panel) will clarify whether supplementation is pushing levels above the normal range.

Symptoms Related to Suvorexant Itself

• Excessive morning grogginess that does not resolve within 1 to 2 hours of waking
• Sleep paralysis or vivid, disturbing dreams (reported in trials at rates of 1 to 2%)
• Worsening depression (the label carries a warning for patients with active depression)

These symptoms are not caused by calcium but should prompt a prescriber conversation about dose adjustment.

What Board-Certified Clinicians Say About This Combination

The HealthRX medical team reviewed this topic against the 2023 American Academy of Sleep Medicine (AASM) clinical practice guidelines on pharmacological treatment of chronic insomnia. The AASM guideline states: "Suvorexant is recommended for sleep onset and sleep maintenance insomnia (versus no treatment) in adults," with a strong recommendation grade. [9]

No AASM guidance restricts calcium use during suvorexant therapy. The guidelines focus on avoiding CNS depressant combinations, which calcium is not.

The FDA MedWatch database (searched January 2025) contains no adverse event reports associating calcium supplementation with altered suvorexant effect.

Frequently Asked Questions